Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 5, 2008, Pages 269-275

  Yamakawa, Tadashi ^a   Takano, Tatsuro ^a   Tanaka, Shun Ichi ^b   Kadonosono, Kazuaki ^a   Terauchi, Yasuo ^c  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b Kanazawa Medical Clinic   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Atorvastatin; Glycemic control; Hyperlipidemia; Pravastatin

Indexed keywords

EID: 56349119861     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E562     Document Type: Article

References (25)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344:1383-1389
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, and Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335:1001-1009
3. Group TL-TIwPiIDLS: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339:1349-1357
4. Collins R, Armitage J, Parish S, Sleigh P, and Peto R; Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 2003; 361:2005-2016
5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, and Fuller JH; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364:685-696
6. Knopp RH, d'Emden M, Smilde JG, and Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care, 2006; 29:1478-1485
7. Sasaki J, Iwashita M, and Kono S: Statins: Beneficial or adverse for glucose metabolism. J Atheroscler Thromb, 2006; 13:123-129
8. Sabatinc MS, Wiviott SD, Morrow DA, McCabc CH, and Canon CP: High dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 Substudy. 2004; 110 (Suppl I):S834
9. Takano T, Yamakawa T, Takahashi M, Kimura M, and Okamura A: Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb, 2006; 13:95-100
10. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, Mabuchi H, Tushima M, Sasaki J, Goto Y, and Ogawa N: Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung, 2002; 52:251-255
11. Yokoyama T, Miyauchi K, Kurata T, Satoh H, and Daida H: Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine 3 coronary after stenting. Atherosclerosis, 2004; 174:253-259
12. Maeda K, Yasunari K, Sato EF, and Inoue M: Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig. Atherosclerosis, 2005; 181:87-92
13. Hayashi T, Rani P JA, Fukatsu A, Matsui-Hirai H, Osawa M, Miyazaki A, Tsunekawa T, Kano-Hayashi H, Iguchi A, Sumi D, and Ignarro LJ: A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis, 2004; 176:255-263
14. Wang J, Tokoro T, Matsui K, Higa S, and Kitajima I: Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci, 2005; 76:2257-2268
15. Hiraoka M, Nitta N, Nagai M, Shimokado K, and Yoshida M: MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/ 2-dependent pathway. Life Sci, 2004; 75:1333-1341
16. Kuzuya M, Cheng XW, Sasaki T, Tamaya-Mori N, and Iguchi A: Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, blocks vascular smooth muscle cell populated-collagen lattice contraction. J Cardiovasc Pharmacol, 2004; 43:808-814
17. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, and Saito Y: Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun, 2004; 324:835-839
18. Kawai T, Tokui M, Funae O, Meguro S, Yamada S, Tabata M, and Shimada A: Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care, 2005; 28:2980-2981
19. Mukhtar RY, Reid J, and Reckless JP: Pitavastatin. Int J Clin Pract, 2005; 59:239-252
20. Chamberlain LH: Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett, 2001; 507:357-361
21. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, and Yada T: Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia, 2006; 49:1881-1892
22. 2+ channels in rat islet beta-cells Br J Pharmacol, 1999; 126:1205-1213
23. Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, Oikawa S, Yamada N, and Shimano H: Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb, 2006; 13:329-335
24. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, and Collins D; Veterans Affairs HDL Intervention Trial (VA-HIT): Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care, 2003; 26:1513-1517
25. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, and Wood D: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 2007; 28:88-136